CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, pros...
Taipei, Taiwan and 38 other locations
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abira...
Phase 1
Taipei, Taiwan and 54 other locations
with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm)....
Phase 3
Taipei, Taiwan and 296 other locations
(control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen R...
Phase 2
Taipei, Taiwan and 37 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Taipei, Taiwan and 378 other locations
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutam...
Phase 2
Taipei, Taiwan and 240 other locations
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subject...
Phase 2
Taipei, Taiwan
survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Wo...
Phase 3
Taipei, Taiwan and 322 other locations
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or sec...
Phase 3
Taipei, Taiwan and 158 other locations
compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate...
Phase 3
Taipei, Taiwan and 258 other locations
Clinical trials
Research sites
Resources
Legal